Get started
Author

Paula Rodríguez-Márquez

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
2022 · Paula Rodriguez-Marquez, Maria E. Calleja-Cervantes, et al. · Science Advances · 107
PDF
Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma
2024 · Maria Luisa Palacios-Berraquero, Paula Rodriguez-Marquez, et al. · Blood Advances · 26
Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia
2023 · Cristina Calviño, Candela Ceballos, et al. · Frontiers in Immunology · 25
In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria
2022 · Rebeca Martinez-Turrillas, Angel Martin-Mallo, et al. · Molecular Therapy — Methods & Clinical Development · 22
PDF
RNA-loaded nanoparticles for the treatment of hematological cancers
2024 · Elisa Garbayo, Souhaila H. El Moukhtari, et al. · Advanced Drug Delivery Reviews · 17
CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome
2021 · Paula Rodriguez-Marquez, Maria Erendira Calleja-Cervantes, et al. · Blood · 16
Generation and GMP scale-up of human CAR-T cells using non-viral Sleeping Beauty transposons for B cell malignances
2025 · Begoña Diez, Cristina Calviño, et al. · Molecular Therapy — Methods & Clinical Development · 11
Genetic Engineering in CAR T Cells for Solid Tumors: Current State, Barriers and Future Developments
2025 · Rodrigo A. Redondo-Frutos, Pedro Justicia-Lirio, et al. · Human Gene Therapy · 6
Generation of an induced pluripotent stem cell line (CIMAi001-A) from a compound heterozygous Primary Hyperoxaluria Type I (PH1) patient carrying p.G170R and p.R122* mutations in the AGXT gene.
2019 · Rebeca Martinez-Turrillas, Saray Rodriguez-Diaz, et al. · Stem Cell Research · 4
PDF
IRF2 is an essential transcription factor with pathogenic and prognostic impact in multiple myeloma
2026 · Nahia Gómez-Echarte, Arantxa Carrasco-León, et al. · Blood · 3
Optimization of a Universal Allogeneic CAR-T Cells Combining CRISPR and Transposon-Based Technologies for Treatment of Acute Myeloid Leukemia
2023 · Candela Ceballos Bolaños, Cristina Calviño, et al. · Blood · 3
BCMA CAR-T Cell Phenotype and Functionality Is Affected By Disease Stage of Multiple Myeloma Patients
2022 · Angel Martin-Mallo, Maria Erendira Calleja-Cervantes, et al. · Blood · 1
A myeloid-dormant metabolic transcriptome identifies a poor-prognosis subgroup in hyperdiploid multiple myeloma with targetable vulnerabilities
2026 · Naroa Barrena, Edurne San José-Enériz, et al. · Blood Cancer Journal
PDF
Rational engineering of sdAb-based CAR T cells targeting BCMA enhances antitumor efficacy and persistence in Multiple Myeloma
2026 · Vianca Ibarra-García, Maria E. Calleja-Cervantes, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Improving CRISPR-Cas9 Screens in CAR T Cells: A Refined Method for Library Preparation
2026 · Maider Garnica, Patxi San Martin-Uriz, et al. · Journal of Visualized Experiments
A functional CAR-T cell atlas to unravel regulatory mechanisms of CAR-T therapies
2025 · Sergio Camara-Peña, Paula Rodriguez Marquez, et al. · Blood
PDF
An open CAR-T single-cell atlas to enable in-depth characterization and rational engineering of CAR-T products
2025 · Sergio Camara-Peña, Paula Rodriguez-Marquez, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma
2024 · Maria Luisa Palacios-Berraquero, Paula Rodriguez-Marquez, et al. · Blood
PDF
Identification and Evaluation of Novel Sdab-Based CAR-T Cells Against BCMA with Improved Therapeutic Efficacy for Multiple Myeloma
2024 · Vianca Ibarra-Garcia, Eva Molina, et al. · Blood
P-073 Identification and Validation of Factors Promoting Resistance to CAR-T Therapy in Multiple Myeloma by Genome-Wide CRISPR Screenings
2024 · Paula Rodriguez-Marquez, Yimei Que, et al. · Clinical Lymphoma Myeloma & Leukemia
271 Development and characterisation of humanised scFv CAR-T therapies targeting BCMA against multiple myeloma
2023 · Jorge Illarramendi, Rebeca Martinez-Turrillas, et al. · Regular and Young Investigator Award Abstracts
PDF
POSTER: CT-342 Prolonged Hematologic Toxicity After B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Treatment: From Clinical Data to Ex-Vivo Studies at a Single Center
2023 · Maria Luisa Palacios-Berraquero, Nerea Berrastegui, et al. · Clinical Lymphoma Myeloma & Leukemia
CT-342 Prolonged Hematologic Toxicity After B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Treatment: From Clinical Data to Ex-Vivo Studies at a Single Center
2023 · Maria Luisa Palacios-Berraquero, Nerea Berrastegui, et al. · Clinical Lymphoma Myeloma & Leukemia
PDF
Works count: 24
Citation count: 240
H-index: 7
I10-index: 7
Year
Topic
Type